Phase 2b Study of GSK4532990 in Adults With NASH
Public ClinicalTrials.gov record NCT05583344. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
17 β-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Nonalcoholic Steatohepatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.
Study identification
- NCT ID
- NCT05583344
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 284 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2, 2023 (Actual)
- Primary completion
- Jan 31, 2026 (Actual)
- Completion
- Sep 18, 2026 (Estimated)
- Last update posted
- Sep 18, 2026
2023 – 2026
United States locations
- U.S. sites
- 80
- U.S. states
- 25
- U.S. cities
- 71
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Homewood | Alabama | 35209-2629 | — |
| GSK Investigational Site | Chandler | Arizona | 85224 | — |
| GSK Investigational Site | Chandler | Arizona | 85712 | — |
| GSK Investigational Site | Mesa | Arizona | 85381 | — |
| GSK Investigational Site | Jonesboro | Arkansas | 72401 | — |
| GSK Investigational Site | North Little Rock | Arkansas | 72117 | — |
| GSK Investigational Site | Huntington Park | California | 90255 | — |
| GSK Investigational Site | La Jolla | California | 92037 | — |
| GSK Investigational Site | Orange | California | 92866 | — |
| GSK Investigational Site | Poway | California | 92064 | — |
| GSK Investigational Site | Rialto | California | 92377 | — |
| GSK Investigational Site | Sacramento | California | 95817 | — |
| GSK Investigational Site | San Francisco | California | 94115 | — |
| GSK Investigational Site | Santa Ana | California | 92704 | — |
| GSK Investigational Site | Van Nuys | California | 91405 | — |
| GSK Investigational Site | Colorado Springs | Colorado | 80907 | — |
| GSK Investigational Site | Bradenton | Florida | 34209 | — |
| GSK Investigational Site | Coral Gables | Florida | 33134 | — |
| GSK Investigational Site | Fort Myers | Florida | 33907 | — |
| GSK Investigational Site | Hallandale | Florida | 33009 | — |
| GSK Investigational Site | Hialeah | Florida | 33016 | — |
| GSK Investigational Site | Homestead | Florida | 33032-8185 | — |
| GSK Investigational Site | Jupiter | Florida | 33458 | — |
| GSK Investigational Site | Lakewood Rch | Florida | 34211 | — |
| GSK Investigational Site | Miami | Florida | 33122 | — |
| GSK Investigational Site | Miami | Florida | 33126 | — |
| GSK Investigational Site | Miami | Florida | 33176 | — |
| GSK Investigational Site | Miami Lakes | Florida | 33016 | — |
| GSK Investigational Site | West Palm Beach | Florida | 33401 | — |
| GSK Investigational Site | Athens | Georgia | 30607 | — |
| GSK Investigational Site | Atlanta | Georgia | 30328 | — |
| GSK Investigational Site | Marietta | Georgia | 30060 | — |
| GSK Investigational Site | Snellville | Georgia | 30078 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46202 | — |
| GSK Investigational Site | South Bend | Indiana | 46635-1557 | — |
| GSK Investigational Site | Iowa City | Iowa | 52242 | — |
| GSK Investigational Site | Topeka | Kansas | 66606 | — |
| GSK Investigational Site | Bastrop | Louisiana | 71220-5035 | — |
| GSK Investigational Site | Marrero | Louisiana | 70072 | — |
| GSK Investigational Site | Metairie | Louisiana | 70006 | — |
| GSK Investigational Site | Monroe | Louisiana | 71201 | — |
| GSK Investigational Site | Shreveport | Louisiana | 71105 | — |
| GSK Investigational Site | Columbia | Maryland | 21045 | — |
| GSK Investigational Site | Greenbelt | Maryland | 20770 | — |
| GSK Investigational Site | Ann Arbor | Michigan | 48109-5000 | — |
| GSK Investigational Site | Southfield | Michigan | 48075 | — |
| GSK Investigational Site | Ypsilanti | Michigan | 48197 | — |
| GSK Investigational Site | Chesterfield | Missouri | 48038 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89106 | — |
| GSK Investigational Site | Princeton | New Jersey | 08648 | — |
| GSK Investigational Site | Sparta | New Jersey | 07871 | — |
| GSK Investigational Site | New York | New York | 10029 | — |
| GSK Investigational Site | New York | New York | 10033 | — |
| GSK Investigational Site | New York | New York | 10075-0999 | — |
| GSK Investigational Site | Chapel Hill | North Carolina | 27599 | — |
| GSK Investigational Site | Durham | North Carolina | 27710 | — |
| GSK Investigational Site | Morehead City | North Carolina | 28557 | — |
| GSK Investigational Site | Akron | Ohio | 44320 | — |
| GSK Investigational Site | Springboro | Ohio | 45066 | — |
| GSK Investigational Site | Westlake | Ohio | 44145-1493 | — |
| GSK Investigational Site | Lancaster | Pennsylvania | 17604-3200 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15213-3204 | — |
| GSK Investigational Site | Wyomissing | Pennsylvania | 19610 | — |
| GSK Investigational Site | Chattanooga | Tennessee | 37421-1605 | — |
| GSK Investigational Site | Clarksville | Tennessee | 37040 | — |
| GSK Investigational Site | Austin | Texas | 78757-8066 | — |
| GSK Investigational Site | Brownsville | Texas | 78520 | — |
| GSK Investigational Site | Dallas | Texas | 75203 | — |
| GSK Investigational Site | Edinburg | Texas | 78539 | — |
| GSK Investigational Site | Georgetown | Texas | 78626 | — |
| GSK Investigational Site | Houston | Texas | 77030 | — |
| GSK Investigational Site | Houston | Texas | 77079 | — |
| GSK Investigational Site | Houston | Texas | 77090 | — |
| GSK Investigational Site | San Antonio | Texas | 78215 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | Waco | Texas | 76710 | — |
| GSK Investigational Site | West Jordan | Utah | 84088 | — |
| GSK Investigational Site | Richmond | Virginia | 23229 | — |
| GSK Investigational Site | Richmond | Virginia | 23236 | — |
| GSK Investigational Site | Seattle | Washington | 98105-4093 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 90 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05583344, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 18, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05583344 live on ClinicalTrials.gov.